SFSandy Fabre

Sandy Fabre

*This is an algorithmically generated author record based on publicly available information.

Sandy Fabre has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Adeline Cathala

    University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France

    1 shared publication
  • Andrea Bari

    Aelis Farma, Bordeaux, France

    1 shared publication
  • Arnau Busquets-Garcia

    Cell-Type Mechanisms in Normal and Pathological Behavior Research Group, Neuroscience Research Program, Hospital del Mar Research Institute, Barcelona, Spain

    1 shared publication
  • Bastien Redon

    University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France

    1 shared publication
  • Caroline A. Arout

    Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, USA

    1 shared publication
  • Charles W. Schindler

    Behavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, USA

    1 shared publication

Latest Publications

  • Open Access

    Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials

    by Margaret Haney, Monique Vallée, Sandy Fabre, Stephanie Collins Reed, Marion Zanese, Ghislaine Campistron, Caroline A. Arout, Richard W. Foltin, Ziva D. Cooper, Tonisha Kearney-Ramos, et al.

    Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi). AEF0117 selectively inhibits a subset of intracellular effects resulting from Δ9-tetrahydrocannabinol (THC) binding without modifying behavior per se. In mice and non-human primates, AEF0117 decreased cannabinoid self-administration and THC-related behavioral impairment without producing significant adverse effects. In single-ascending-dose (0.2 mg, 0.6 mg, 2 mg and 6 mg; n = 40) and multiple-ascending-dose (0.6 mg, 2 mg and 6 mg; n = 24) phase 1 trials, healthy volunteers were randomized to ascending-dose cohorts (n = 8 per cohort; 6:2 AEF0117 to placebo randomization). In both studies, AEF0117 was safe and well tolerated (primary outcome measurements). In a double-blind, placebo-controlled, crossover phase 2a trial, volunteers with CUD were randomized to two ascending-dose cohorts (0.06 mg, n = 14; 1 mg, n = 15). AEF0117 significantly reduced cannabis’ positive subjective effects (primary outcome measurement, assessed by visual analog scales) by 19% (0.06 mg) and 38% (1 mg) compared to placebo (P < 0.04). AEF0117 (1 mg) also reduced cannabis self-administration (P < 0.05). In volunteers with CUD, AEF0117 was well tolerated and did not precipitate cannabis withdrawal. These data suggest that AEF0117 is a safe and potentially efficacious treatment for CUD.ClinicalTrials.gov identifiers: NCT03325595, NCT03443895 and NCT03717272.